Michael Wendt, PhD
Associate Professor of Internal Medicine-Hematology, Oncology and Blood and Marrow Transplantation
Current Positions
- Associate Professor of Internal Medicine-Hematology, Oncology and Blood and Marrow Transplantation
Education
- PhD, Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin
- Postdoctoral Fellow, Pharmacology, University of Colorado, Denver, Colorado
- Postdoctoral Research Scholar, General Medical Sciences (Oncology), Case Western Reserve University, Cleveland, Ohio
Graduate Program Affiliations
Selected Publications
- Coleman MF, Kuloylouoglu Cotul E, Pfeil AJ, Devericks EN, Chen H, Kiesel VA, Safdar MH, Teegarden, D, Hursting SD, Wendt MK. Hypoxia-mediated suppression of pyruvate carboxylase drives tumor microenvironment immunosuppression. BioRxiv. doi: https://doi.org/10.1101/2022.04.06.487050
- Chen H, Cresswell G, Libring S, Ayers M, Miao J, Zhang ZY, Solorio L, Ratliff T, Wendt MK. Tumor-cell autonomous SHP2 contributes to immune suppression in metastatic breast cancer. Cancer Research Communications. (2022) 2 (10): 1104–1118.
- Shinde A, Kulkoyluoglu Cotul E, Chen H, Smith A, Libring S, Solorio L, Wendt MK. Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer. Mol Biomed, (2022) 3(1):19.
- Akhand SS, Purdy SC, Liu Z, Anderson JC, Willey CD, Wendt MK. Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. NPJ Breast Cancer, Jan 21st (2021) 21;7(1):5
- Abdullah A, Akhand SA, Paez JS, Brown W, Pan L, Libring S, Badamy M, Dykhuizen E, Solorio L, Tao WA, Wendt MK. Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug resistant breast cancer. Oncogene. (2020)40(2):322-333.